A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicent… (NCT07449429) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US
10 participantsStarted 2026-02-28
Plain-language summary
This study develops and validates a privacy-preserving OCR-LLM pipeline that converts admission history of present illness (HPI) records into structured coronary syndrome subtypes (STEMI, NSTEMI, unstable angina, and chronic coronary syndrome). The system first extracts text from de-identified HPI images using locally deployed OCR, then applies large language models with a fixed diagnostic prompt to generate subtype classification and evidence. Performance is evaluated in an internal validation cohort and multiple external datasets covering heterogeneous EHR templates, emergency department cases, and an English dataset from MIMIC-IV. A clinician usability study assesses changes in diagnostic accuracy and time with and without tool assistance.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:Hospital encounters with admission HPI documenting sym
2a4afaef-9dc1-47fc-874f-9dffaf7…
evant to coronary syndrome subtyping.
Cases with sufficient documentation to assign one of four target subtypes (STEMI, NSTEMI, UA, CCS) by adjudication.
\-
Exclusion Criteria: Unclear subtype or incomplete/uncertain time information preventing gold standard assignment.
Non-CHD primary reason for admission after screening (for MIMIC-IV cohort).
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing an AI system that reads admission notes to classify what type of heart attack or coronary syndrome a patient has — how might that kind of tool affect the accuracy or speed of my own diagnosis if I were treated at a participating hospital?
2Since this study is focused on validating an AI classification system rather than testing a new treatment, would being involved in this research change anything about the actual medical care or medications I would receive?
3The trial isn't recruiting yet and spans hospitals in both China and the US — do you know when it might open, and whether any sites near us are expected to participate?
4Because this is listed as 'Phase NA,' it sounds more like a diagnostic validation study than a drug trial — can you help me understand what participating would actually involve for me as a patient, and whether my medical records or notes would be used?
5Given that my diagnosis involves acute coronary syndrome, are there standard treatment pathways or other studies you'd recommend I consider first while this AI validation trial is still in the preparation stage?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall classification accuracy
Timeframe: 1 month
Trial details
NCT IDNCT07449429
SponsorChina National Center for Cardiovascular Diseases